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Occurrence of venomous snakebites
There are about one million venomous snakebites reported each year
(Gonzalez, 1991) of which more than 30,000 are fatal (Tu, 1977; White, 1995;
Warrell, 1996). Table 1 lists the approximate number of annual deaths around
the world as a result of venomous snake encounters. The number of lethal
incidents is higher in the less developed areas of the world due to increased
encounters and decreased use of effective antivenom treatments (Underwood,
1979; Warrell and Fenner, 1993). In the United States, the number of annual
venomous snakebite poisonings is roughly 8,000 with less than one half of one
percent being fatal (Gomez and Dart, 1995). The 9 to 14 yearly fatal,ities
typically occur in small children and persons over 70 years of age, especially with
poorly handled medical treatment (Russell, 1996; Warrell, 1996). The vast
majority of these bites are due to species within the Viperidae sub-family
Crotalinae (Litovitz et al., 1991; Gomez and Dart, 1995). Representative species
in this sub-family include the Western Diamondback rattlesnake (Crotalus atrox),
the Prairie Rattlesnake (Crotalus viridis viridis) and the Broad-banded
Copperhead (Agkistrodon contortrix laticinctus). Most of the serious bites,
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though, are caused by rattlesnakes (Parrish, 1965; Gomez and Dart. 1995;
Russell, 1996; Warrell, 1996). Russell (1996) found that over 60 percent of
envenomations in the United States were caused by Crotalus and Sisturus, the
two genus of rattlesnakes, slightly more than 21 percent for Agkistrodon
(copperhead and cottonmouth) species and less than 1 percent as a result of
Elapid (coral snake) encounters. This literature review will concentrate on the
composition of crotalid venom and treatment of crotalid envenomations. It will
not cover other members of the Viperidae family, such as the true vipers, nor the
Elapids (cobras and mambas) or Hydrophids (sea snakes). Table 2 lists the
scientific and common names of some representative species from the family
Crotalidae in North America.
Treatment of venomous snakebites
The literature covering the treatment of venomous snakebites around the
world is not only quite extensive, but also very similar in content. This review
therefore covers primarily topics specifically referring to North American or
Crotalid envenomation and treatment. Other references outside this parameter
are cited only where applicable. The theories behind treatment of venomous
snakebites are as old as recorded history, and have roots in both folk and.
contemporary medicine. Such folk and modern treatments have been thoroughly
3
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described elsewhere. but Gomez and Dart (1995) and Russell (1996) provide an
adequate review of recent snakebite treatment literature. The primary goal of
medical treatment is to reduce mortality and morbidity. Recent medical
advances, particularly the improved production and use of antivenom, have
lowered the already small number of snakebite related deaths (Parrish, 1965;
Russell, 1983; Russell, 1996). However, the prevalence of local tissue damage,
despite the use of antivenom or other therapy, remains an issue of medical
concern (Ownby et al., 1983; Lomonte et al., 1993; Rucavado and Lomonte,
1996).
Traditional folk remedies are often more ritualistic than they are practical,
as the use of poultices, bandages, herbs. teas or primitive incisions and suction
of the affected area do I:itUe more than give peace of mind to the victim. Modern
medicine is only slightly more effective at reducing the local tissue damage
caused by snake venom. The practice of cryotherapy, fasciotomy, tourniquets,
electro-shock therapy and other modern techniques have not only been shown to
be ineffective, but are also not recommended (Gomez and Dart, 1995; Russell,
1996). The recommended first-aid listed by Gomez and Dart (1995) and Russell
(1996) include: (1) retreat out of the striking distance of the snake, (2) reassure
the victim; try to keep calm. (3) immobilize the limb or affected region, and (4)
transport the victim to a medical facihty as soon as possible. Ice, tourniquets or
oth~r constrictive bands, food or fluids, and any primitive techniques which cause
potential harm, such as excision therapy, are contraindicated. Many of the first-
aid and hospital techniques, both past and present, are performed out of the
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urgency that something must be done. Such practices may ease the mind of the
patient, but they often do more harm than good. To date, the only truly effective
treatment for snakebites is the use of antivenom (Wingert, 1991; Meier, 1995;
White, 1995). The possibility of other effective treatments for snakebites is
currently under investigation.
The first-aid procedures listed by most authors necessitate the
immobilization of the victim, and the transport of the patient to a hospital as
quickly as possible. First-aid should not substitute for treatment at a medical
facility. One of the most important aspects of the prehospital scenario is to calm
the snakebite victim. Warrell (1996) describes how anxiety following a bite can
potentiate those signs common to envenomation. Reassurance from bystanders
emphasizing that most bites are not fatal aids in keeping the victim's physical
mobility at a minimum. The other important consideration of the prehospital
stage is to "do no harm" (Hardy, 1992; White, 1995). The application of
tourniquets, or other constricting bands, the use of ice and the practice of
excision therapy (the "cut and suck" method) should never be attempted,
especially by the layperson (Gomez and Dart, 1995; Russell, 1996). A 1984
committee meeting of the American Association of Poison Control Centers and
the American College of Physicians also decided that such primitive practices
are to be discouraged (Wingert, 1991; Gold, 1996). White (1995) also adds that
no food or oral fluids, especially alcohol, should be given. The only prehospital
treatment that is acceptable is the establishment of an intravenous access and
the administration of oxygen, if necessary (Gomez and Dart, 1995). While the
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guidelines of immobilization of the affected region, urgency to reach a medical
facility and "do no harm" are fairly constant throughout the literature, some slight
variations in first-aid protocol do exist. Russell (1996) favors the cleansing of the
envenomated region with soap and water, but White (1995) advises against
major cleaning techniques. Gold (1996) also stipulates the use of negative
pressure devices if used within the first five minutes after the bite. This approach
does not violate the lido no harm" rule, as it does not advocate incisions made by
the layperson. However, White (1995) discourages the application of any kind of
suction to the wound.
The ultimate goal of the medical treatment protocol is controlling shock,
neutralizing venom action, and preventing secondary infection. Gomez and Dart
(1995), Russell (1996) and Wingert (1991) also provide excellent reviews of
hospital procedures. Once at the medical facility, the patient must first be
evaluated for any immediate life-threatening conditions, such as hypovolemic
shock or respiratory failure. Medical staff should also consider treating any first-
aid attempts, such as tourniquets, that have been inappropriately performed or
that may hinder further therapy. Care should be taken when removing any
tourniquets, as the sudden flow of blood may induce shock, and should only be
performed after an intravenous access has been established (Gomez and Dart,
1995). Russell (1996) recommends gradually applying bands of less and less
constriction prior to removing a tightly bound tourniquet. The timing of any
subsequent treatment, namely antivenom therapy, becomes the judgment of
trained medical personnel. Only when the snakebite victim is stable can medical
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personnel truly assess the severity of the envenomation or consider further
treatment.
The course of further treatment depends on a number of factors,
particularly the species of snake involved in the envenomation and the severity
of the bite (Wingert, 1991; Gomez and Dart, 1995; Russell, 1996). The type of
snake involved in the bite is important to determine since different species'
venoms induce different types of damage. For example, the major symptom of
Crotalid envenomation is local tissue damage, possibly to the point of complete
dysfunction (Mebs and Ownby, 1990; Lomonte, 1994; Warrell, 1996). The
primary signs of Elapid envenomation are neurotoxic in nature (Gomez and Dart,
1995). A list of the most common symptoms of rattlesnake venom poisoning is
provided in Table 3. Determination of the type of snake allows selection of the
appropriate antivenom, if any, to be used in treatment. The severity of
envenomation will then dictate not only the use of antivenom, but also the
quantity of antivenom to be administered (Wingert, 1991; Russell, 1996;
Theakston, 1996). Russell (1996) contends that antivenom need not be used in
cases of minimal envenomation. In fact, nearly 25 percent of Crotalid bites do
not result in envenomation (Wingert, 1991; Gomez and Dart, 1995; Russell,
1996). Wingert (1991), however, suggests that antivenom should be
administered in cases of minimal envenomation for the true magnitude of bite
TABLE 3
INCIDENCE OF SYMPTOMS OF RATTLESNAKE VENOM POISONING
Symptom or Sign Incidence Symptom or Sign Incidence
Fang marks 100% Increased blood clotting time 37%
Swelling and edema 74% Decreased hemoglobin 37%
Weakness 70% Thirst 36%
Pain 65% Necrosis 27%
Numbness of tongue, mouth 63% Abnormal electrocardiogram 26%
or scalp or feet
Changes in pulse rate 60% Glycosuria 20%
Numbness of affected part 57% Increase salivation 20%
Faintness or dizziness 57% Sphering of red blood cells 18%
Blood pressure changes 54% Proteinuria 16%
Ecchymosis 51% Cyanosis 16%
Sweating and/or chills 43% Increased blood platelets 16%
Nausea, vomiting or both 42% Hematemesis, hematuria, or 15%
melena
Changes in body temperature 42% Unconsciousness 12%
Decreased blood platelets 42% Blurring of vision 12%
Fasciculations 41% Swollen eyelids 7%
Swollen regional lymph nodes 40% Muscle contractions 6%
Vesiculations 40% Retinal hemorrhage 5%




severity might be delayed. The theories and techniques of antivenom
administration are covered fater. The degree of envenomation is determined by
the local signs, laboratory tests and systemic signs.
Common sequelae of Crotalid envenomation
In North America, in addition to the systemic effects, the most common
sequelae of local tissue damag.e caused by envenomation by Crotalid species
are edema, hemorrhage and myonecros'is (Mebs and Ownby, 1990; Rucavado
and Lomonte, 1996; Gutierrez et al., 1996). Edema jls thought to be associated
with endothelial damage, with subsequent increases in vascular permeability
leading to loss of plasma fluid into the affected region producing swelling
(Wingert, 1991; L10ret and Moreno, 1993). Edema can also occur through the
presence of exogenous autocoids in the venom, or by the release of
endogenous autocoids induced by the venom (Lamonte, 1994). Erythema can
also be associated with vasodilation and other alterations in vascular flow.
Hemorrhage induced by snake venom is often the result of certain venom toxins
causing adverse structural problems within the vascular endothelia (Bjarnason
and Fox, 1988; Ownby, 1990). Red bliood cells can then escape the vessels per
rhexis or per diapedes;s (Ownby, 1990; Lomonte, 1994). Petechia and
ecchymosis are the most immediate identifying signs that hemorrhage is
occurring (Wingert, 1991; Gomez and Dart, 1995; Russetl, 1996; Warrell, 1996).
Myonecrosis is the result of venom toxins directly disrupting the pl1asma
membranes of the muscle cells (Ownby, 1990; Mebs and Ownby, 1990; Tu,
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1991; Lomonte, 1994). Myonecrosis can also occur indirectly via ischemia of the
muscle mass produced by the disruption of blood flow to the region (Gutierrez
and Lomonte, 1989; Ownby, 1990; Harris and Cullen, 1990). In this fashion,
hemorrhagic toxins may contribute to the total myonecrosis (Ownby, 1990;
Lomonte, 1994). The overall myotoxic effect is typically not seen grossly for
several days to several weeks (Warrell, 1996). An overview of the specific toxins
in snake venom that produce these effects is presented later.
Evaluation of the degree of envenomation
Though the various guidelines used to judge the severity of North
American envenomations and recommendations as to the amount of antivenom
to administer have been widely discussed in recent literature, Wingert (1991),
Gomez and Dart (1995) and Russell (1996) provide a concise review. These
medical descriptions are also listed in Table 4. The most common signs of
envenomation are pain, swelling, hemorrhage and tissue loss, and generally
occur in relation to the amount of venom injected (Wingert, 1991; White, 1995).
Snakebites resulting in no or minor envenomation produce minor swelling and
possibly occult hemorrhage that is limited to the site of the bite. Systemic signs
are typically absent with no abnormal laboratory findings. Moderate
envenomation includes edema and eccymosis that include a majority of the
affected extremity. Systemic signs, such as nausea, vomibng, paresis and mild,
hypotension are typically present, but not life-threatening. Minor coagulation
abnormalities of the blood may also be present. Severe envenomation includes
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signs of local tissue damage that involves the entire extremity and spread
rapidly. Systemic anomalies are seen as dementia, paralysis, cardiac
arrhythmias and possible respiratory failure. Coagulation is often severely
impaired and urinalysis often reveals hematuria. White (1995) and Warrell
(1996) also indicate the prevalence of renal failure in moderate to severe
envenomation. Wingert (1991) also suggests the use of immuno-diagnosis in
aiding to evaluate the severity of envenomation. Detection of specific levels of
venom antigens in the victim's blood would provide a clearer picture as to how to
treat a snakebite victim or how much antivenom to use (Riviere et al., 1997). At
present, there are few studies regarding the detection of venom in the blood of
snakebite victims, especially those involving Crotalids. Both moderate and
severe envenomations warrant the use of antivenom.
Antivenom
A review of the description of antivenom and the antivenom producing
process is provided by Chippaux and Goyffon (1991) and Dart and Horowitz
(1996). Antivenom is animal serum, usually horse or sheep, that contains
antibodies specific for the toxins found in snake venoms. It is made by injecting
J2
TABLE 4
DEGREE OF ENVENOMATION AND ANTIVENOM TREATMENT
REQUIREMENTS
Degree of Envenomation and Symptoms Vials of Antivenom (1 vial=10ml)
No envenomation 0
Fang marks present with no local or systemic reactions
Minimal envenomation
Edema, erythema, ecchymosis limited to site of bite.
Minor systemic signs such as nausea, mild hypotension may
or may not be present
Coagulation parameters normal
Moderate envenomation
Edema, erythema, ecchymosis present in most of extremity
Systemic signs such as nausea, hypotension, tachycardia
and tachypnea present but not life threatening
Coagulation parameters may be abnormal with decreases in
both platelets and fibrinogen
Severe envenomation
Edema, erythema, ecchymosis involving entire extremity
Marked systemic signs such as dementia, hypotension,
respiratory distress present and may be life threatening
Coagulation parameters abnormal, with spontaneous bleeding,




Compiled from Wingert (1991), Gomez and Dart (1995) and Russell (1996)
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small amounts of venom from one or more species into an animal, thus
producing a humoral response resulting in the formation of antibodies to the
toxins. The serum from these animals can then be collected and administered to
a snakebite victim, with the hope that the already formed antibodies will
neutralize circulating venom toxins. Monovalent antivenom is made using venom
from only one species while polyvalent antivenom is made using venom from two
or more snake species. The final antivenom solution consists largely of the
F(ab')2 regions of the immunoglobulins (Dart and Horowitz, 1996). Investigators
have been using the F(ab')2 fractions in order to not only increase the efficacy of
the antivenom, but decrease potential. adverse reactions to antivenom therapy,
such as anaphylaxis and serum sickness. The idea is that by using smaller
F(ab')2 region rather than the whole IgG molecule, the antivenom would be able
to penetrate tissues faster (Dart and Horowitz, 1996; Consroe et al., 1996;
Scherrmann and Pepin, 1996; Grandgeorge et ai, 1996; Landon and Smith,
1996). Digesting the IgG molecule above the disulfide bond with papain
produces two separate Fab regions and a Fc domain, while dissolving the
immunoglobulin below the disulfide bond with pepsin allows the two Fab
fractions to remain attached as a F(ab')2 molecule. Riviere et al. (1997), though,
demonstrated that the F(ab')2 region provided greater venom neutralization than
the smaller Fab molecule, as it causes a higher redistribution of venom into the
vascular space. Venom is more effectively neutralized in the vascular
compartment than in the extravascular space.
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Different regions of the world have different antivenoms, as they are made
from the species found in that geographical location. The only Crotalid
antivenom used in North America is Wyeth's Polyvalent Antivenin, which is made
using the venoms of Crotalus atrox, Crotalus adamanteus, Crotalus durissus
terrificus and Bothrops atrox (Wingert, 1991; Gomez and Dart, 1995). The
common names of these species are Western Diamondback Rattlesnake,
Eastern Diamondback Rattlesnake, South American Rattlesnake and Fer-de-
lance, respectively.
A summary of the proper use and dosage of antivenom in snakebite
therapy is given by Gomez and Dart (1995) and Russell (1996) and is presented
in Table 4. The administration of Crotalid antivenom is based upon the degree
of envenomation. Gomez and Dart (1995) state the recommended dose as 10
vials for moderate to severe envenomations and up to 20 vials in severe cases
presenting with extensive hemodynamic abnormalities. Russell (1996) lists a
range of 5 to 30 vials of antivenom for moderate to severe envenomation,
respectively. Both authors suggest that the reconstituted antivenom should be
administered as a 1:10 to 1:15 dilution by adding it to 500 to 1500cc of
physiologic saline or crystalloid within the first few hours after the bite. Wingert
(1991) also supports the previously described procedure for antivenom
administration. These authors suggest that the first infusions be made slowly in
order to properly monitor for anaphylactic reactions. More antivenom can then




Most physicians state that antivenom solution should always be given
intravenously (Chippaux and Goyffon, 1991; Gomez and Dart, 1995; Russell,
1996), however some recommend administration of 5 to 10 cc of the
reconstituted, but not diluted, antivenom around the site of the bite (Package
Insert). However, Chippaux and Goyffon (1991) advises against subcutaneous
administration of antivenom, as it is painful and weakly effective. Antivenom can
be given in the deep muscles of the thigh (Chippaux and Goyffon, 1991; Warrell
1995), but only if venous access is not readily available. Intramuscular
infusions, however, are discouraged by Gomez and Dart (1995). Antivenom
should not be injected into fingers or toes (Gomez and Dart, 1995). Although
there is controversy as to how long after a bite immuno-therapy becomes futile,
antivenom should be given as soon as possible. Russell (1996) claims
antivenom therapy is of little value for most local and some systemic signs 12
hours post envenomation, but advocates its use 30 hours after envenomation for
treating coagulopathy. Wingert (1991) used mouse models to extrapolate this
time out to 60 hours. These extended times are in regards to systemic effects.
Antivenom has been shown to have very little neutralizing effect of local damage,
even when administered immediately following experimental envenomati'on
(Russell, 1973; Rucavado and Lomonte, 1996).
Complications of antivenom therapy
The ultimate goal of antivenom therapy is to reduce morbidity and
mortality resulting from envenomation. However, antivenom therapy has both
16
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local and systemic consequences. While antivenom is effective at reducing
mortality, it is often ineffective at reducing the local morbidity at the site of the
bite (Ownby et al., 1983; Lomonte et al., 1993a; Rucavado and Lomonte, 1996).
The failure of antivenom to inhibit local tissue reactions is not only a problem
associated with time, but also its accessibility to the venom. Not only is the
average time to a medical facility in developed countries around 60 minutes
(Arnold, 1982), but medical assessment depends on the formation of the local
signs in order to determine the proper course. Such evaluations also add time
before treatment. Additionally, research has shown that antivenom may not
have the capacity to neutralize all of the toxins within venom that are responsible
for local tissue damage (Dart and Horowitz, 1996). For example, Ownby and
Colberg (1987) showed that Wyeth's Polyvalent (Crotalidae) antivenom contains
few antibodies to the toxins of one species of rattlesnake (Crotalus viridis viridis).
Ownby et al. (1984) also showed that Wyeth's polyvalent (Crotalidae) antivenom
did not effectively neutralize myotoxin a, which plays a crucial role in the
development of muscle damage following prairie rattlesnake envenomation,
when experimentally injected into mice. However, the total time prior to
antivenom treatment is typically soon enough to fight severe systemic reaction
induced by the venom and therefore eliminate the chances of fatalities (Ownby
et al., 1984; Chippaux and Goyffon, 1991). This situation has prompted interest
into the development of an appropriate and medically efficacious first-aid
therapy.
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Another drawback of antivenom therapy is its potential to induce
anaphylactic shock. The nature of the relationship between antivenom and
adverse reactions are well documented Gomez and Dart (1995), Warrell (1996)
and Chippaux and Goyffon (1991). Since the antivenom is made from horse or
sheep serum, the patient's immune system may react immunologically with the
foreign antibodies. Signs of anaphylaxis include utricaria, itching, hypotension
and respiratory distress. This adverse response to antivenom is primarily caused
by diffuse activation of the complement cascade, as opposed to type I
hypersensitivity (Warrell, 1995). This acute systemic reaction should not be
confused with the systemic reactions that are the result of the damage to vital
organs due to venom toxins. Shock is a physio ogical response to either the
presence of foreign proteins or the psychological trauma of having been bitten.
Damage to the internal organs such as the heart or kidneys generally takes
several hours. It is this damage that antivenom is designed to prevent.
Research has also indicated a common occurrence, possibly as high as
75% (Gomez and Dart, 1995; Consroe et al., 1995) of serum sickness in patients
who receive more than 5 vials of antivenom (Wingert, 1991; Gomez and Dart,
1995). Serum sickness is a delayed serum reaction, or type III hypersensitivity
that occurs days to weeks following antivenom therapy. It is caused by
conglomerations of antigen-antibody complexes lodged within tissues, especially
the kidney.. Signs of serum sickness include utricaria, swollen joints,
lymphadenopathy, and proteinuria (Wingert, 1991; Gomez and Dart, 1995). The
adverse reactions related to initial antivenom infusions can be reduced by
18
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concomitant administrations of epinephrine and! or histamine blocking agents,
such as diphenhydramine HCL (Wingert, 1991; Gomez and Dart, 1995; Russell,
1996). The appropriate treatment for serum-sickness is corticosteroid therapy
(Wingert, 1991).
Controversial treatments of Crotalid envenomaUon
While antivenom therapy is the most effective route in treating venomous
snakebites, other techniques, such as tournique,ts, fasciotomies, cryotherapy,
corticosteroids and electro-shock are still controversial. The debates on these
alternative snakebite treatment methods are reviewed in Wingert (1991), Gomez
and Dart (1995) and Gold (1996). Tourniquets or other constrictive bands are
perhaps the most common first-aid techniques applied in the field. It is thought
that the constriction of blood flow inhibits the spread of the venom into systemic
circulation, but the tourniquet itself could exacerbate local damage. As swelling
progresses against the pressure of the band, ischemia increases, as does the
venom effects on the already damaged tissues. Animal studies using the
Sutherland compression immobilization method showed that an elastic band that
constricts only the superficial venous and lymphatic flow, yet permits the flow of
arterial supply, retards the spread of the venom without an increase in local
damage (Warrell, 1995). However, the inconsistency of band application by the
layperson allows this technique to remain controversial and discouraged as an
acceptable form of first-aid.
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Fasciotomy is another alternative snakebite treatment that is widely
disputed. The technique entails surgically incising tissue fascia in order to
relieve increasing pressure caused by continued swelling and has not proved to
be effective at treating the local signs of envenomation (Warrell, 1995). Gomez
and Dart (1995) and Russell (1996) advocate its use only if arterial supply is
clearly impaired or compartmental syndrome is evident. Synder (1991) proposes
that a fasciotomy might be the only treatment capable of saving an affected hand
or foot. Russell (1996) adds, that despite the presence of profound edema in
Crotalid bites, vascular compromise rarely occurs. Sutherland et a/. (1979) and
Snyder (1991) demonstrated that properly applied ligatures and surgical
excision, respectively, could reduce the tissue uptake of venom and overall
damage, but these experiments were performed in controlled and/or sterile
environments.
Corticosteroids are another popular, and highly debated, treatment for
venomous snakebites. There is no clear indication that their use has any
therapeutic effect against the venom toxins (Arnold, 1982; Burch et a/., 1988)
and the administration of steroids in snakebite cases should be reserved for
treatment of anaphylactic reactions (Gomez and Dart, 1995; Russell, 1996).
Cunnigham et a/. (1979) demonstrated that concurrent use of corticosteroids
while experimentally injecting Crotalus adamanteus venom dramatically
increased lethality.
Cryotherapy is another alternative treatment which can do more harm
than good. It was once thought that vasoconstriction due to cold would decrease
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the spread of venom, and that the cold itself would inhibit the venom action.
Wingert (1991) describes that freezing already poisoned tissues adds to the
overall necrosis and that low temperatures do not diminish the proteolytic action
of venom enzymes. The use of cryotherapy is discouraged by most medical
professionals.
The practice of electroshock therapy is perhaps the most "one-sided"
controversial topic of snakebite treatment. The recent fervor upholding its use
occurred when Guderian at al. (1986) reported the success of electrical current
to treat snakebite in the Woarani Indians in Ecuador, but the practice of
electroshock therapy has been around since the turn of the century (Gold, 1995).
Though some believe that electricity shortens the half-life of the venom
(Guderian at al., 1986), or alters the hydrogen ion structure of the venom toxins
(Kroegel and Meyer zum Buschenfelde, 1986), these actions are not consistent
with the chemical or physical properties of the venom (Gold, 1995). Howe (1988)
was unable to show adequate reduction in the spread of venom using
electroshock therapy in rat models. The current interpretation by most
toxinologists is that Guderian treated an "immune" population, as the Woaranis
already had high antibody titers due to the increased number of venomous
encounters in that region (Wingert, 1991; Gold, 1995). The true efficacy of
electroshock therapy has never been proven in controlled studies, and should be
discouraged (Gomez and Dart, 1995; Russell, 1996).
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Research for effective first-aid therapy
The goal of an effective first-aid therapy is to rapidly and effectively
neutralize those components of snake venom that are primarily responsible for
local tissue damage. Specifically, phospholipase A2s are primarily responsible
for myotoxicity (Ownby, 1990; Mebs and Ownby, 1990; Lamonte, 1994) and are
implicated directly and indirectly in the formation of edema (Lomonte, 1994).
Metalloproteinases are responsible for hemorrhage (Bjarnason and Fox, 1988).
Administration of a chemical agent that is antagonistic toward one or more of
these venom constituents soon after a bite could perhaps reduce the overall
brunt of the venom action and therefore decrease the need for extensive therapy
at a medical facility. Melo et al. (1994) investigated the ability of certain extracts
from the plant, Eclipta prostrata, to neutralize myotoxic and hemorrhagic activity
of Crotalid venoms. Melo and Suarez-Kurtz (1988) and Melo et al. (1993) also
showed the ability of heparin and other polyanions to inhibit crotalid venom
action. Earlier work by Ownby et al. (1975) identified a number of substances,
namely procaine HCI and chelating agents like diethylenetriaminepentaacetic
acid (DTPA), as able to antagonize venom components (Ownby and Tu, 1977).
Ownby et al. (1997) demonstrated that para-bromophenacyl bromide (p-BPB), a
PLA2 inhibitor that acts by binding to the histidine residue in the active site of the
enzyme (Volwerk et al., 1974), is an effective antagonist of the myotoxic activity
of a PLA2 myotoxin from Crotalus viridis viridis venom. This PLA2-inhibitor also
antagonizes a PLA2 myotoxin from Agkistrodon contortrix laticinctus venom
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(Melo and Ownby, 1996). Unfortunately, many of these antagonists work onLy in
vitro, not in vivo. That is, the antagonist neutralizes the venom when mixed with
the venom prior to injection, but not when it is aclministered after the injection of
venom. The apparent lack of success of these types of compounds has lead to
the interest in improving antivenom studies. Lomonte et al. (1987; 1990),
Rucavado and Lamonte (1996), Gutierrez et al. (1996) have tested various
methods for neutralizing crotalid venom with antivenom. Again, the in vitro
neutralization capacity of antivenom far surpasses its in vivo capabilities to
reduce local tissue damage. As venomous snakebites are rarely fatal, the goal
of effective first-aid is to combat and eliminate the local damage.
Components of snake venom
Snake venom is a complex mixture of enzymatic and non-enzymatic
proteins designed to incapacitate and kill the prey animal with toxins that either
attack the nervous system, cardiovascular system and/or destroy tissues. It
contains enzymes and other proteins, lipids, carbohydrates, amino acids, amines
and various free ions that act synergistically to produce the overall venom effects
(Tu, 1977; Stocker, 1990). These effects can be seen readily at the level of
muscle tissue either by destroying the tissue itself or by affecting nervous
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transmission at the neuro-muscular junction. Table 5 provides an abbreviated
list of the components of a crotalid venom. Although venom toxins affect all cell
types, toxins are often classified as hemorrhagic, neurotoxic and sometimes
myotoxic. As this literature covers only Crotalid venoms of North America, the
neurotoxic components of snake venom will not be discussed.
Myotoxic Action of Snake Venom
Myonecrosis, and other types of local tissue damage, is characterlstic of
envenomation from snakes of the Crotalidae family (Ownby, 1990; Mebs and
Ownby, 1990). Only a few Crotahd venoms are known to contain neurotoxins,
such as crotoxin and crotoxin-like toxins (Mebs and Ownby, 1990; Lamonte,
1994). All crotalid venoms examined contain myotoxins. This fact should not be
surprising as muscle comprises most of the body's mass and the
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function of snake venom is not only to kill prey, but to begin digestion (Harris and
Cullen, 1990; Dufton, 1993). There are several types of toxins that produce
myonecrosis: small, nonenzymatic proteins; non-neurotoxic myotoxic
phospholipases A2s; and hemorrhagic toxins that also produce myotoxicity
(Ownby etal., 1978; Tu, 1991; Lomonte, 1994). A fourth type could be added by
mentioning the neurotoxic PLA2 that also induce myonecrosis, such as found in
the venom of C. durissus terrificus. A list of the various types of myotoxins is
found in Table 6.
The first group of myotoxins are the small, nonenzymatic proteins. The
best known, and most widely studied is myotoxin a, from C. viridis viridis (Ownby
et aI., 1976; Cameron and Tu, 1977). Myotoxin a is composed of 42 amino acid
residues and has a molecular weight of about 4000 (Fox et aI., 1979). Myotoxin
a dilates the sarcoplasmic reticulum leading to muscle cell damage (Mebs and
Ownby, 1990). The swelling of the cell is due to a change in ion permeability that
eventually leads to the rupture of the plasma membrane, thus inducing cell
death. Another toxin of this type is crotamine, from C. dur;ssus terrificus. It is
also very basic, about the same size as myotoxin a, and its action is nearly
identical (Laure, 1975).
The second and most ubiquitous type of myotoxins are the PLA2s, which
catalyze the hydrolysis of 3-sn-phosphoglycerides at the 2-position (Kini and
Evans, 1989). These toxins can be of the neurotoxic or non-neurotoxic variety.
The non-neurotoxic PLA2s can be further divided into enzymatically and














b Ol • enzymatically-inactive
(4) Indirect myotoxic factors
Lamonte (1994)
* Not found in Crotalid venoms
Characteristics
Basic, non-enzymatic, single chain
peptides of 42-45 a.a.
Basic, non-enzymatic, single chain
proteins of -60 a. a.
Basic, single chain (120 a.a.) or
proteins with PLA2 activity and presynaptic
neurotoxicity.
Basic, single chain (-120 a. a.) or dimeric
proteins with PLA2 structure.
Asp49 PLA2s
Lys-49 (or other variant) PLA2s
May damage skeletal muscle by indirect
mechanisms, perhaps through ischemia
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abridged list of some Crotalid PLA2s is provided in Table 7. However, since a
number of isoforms have been isolated in this group that were unable to
hydrolyze phospholipids due to changes in the amino acid sequence, it is clear
that enzymatic activity is not necessary for myotoxic action (Lomonte and
Gutierrez, 1989; Johnson and Ownby, 1993a; Lamonte, 1994). Recent cloning
and sequencing of the genes coding for these proteins indicated a new class,
K49 PLA2 , which apparently lacks catalytic activity on artificial substrates (Araujo
et al., 1996). With the exception of the myotoxin from Vipera ammodytes
ammodytes (ammodytoxin L), which contains a serine residue, all of the
enzymatically inactive PLA2 have a lysine residue in position 49. Those that are
enzymatically active have aspartate in that position (Lamonte, 1994). Example
of a Lys-49 PLA2 and Asp-49 PLA2 are found in the venoms of A. contortrix
laticinctus (Johnson and Ownby, 1993a) and C. viridis viridis, (Ownby et al.,
1997), respectively. It is speculated that the primary site of action of these PLA2
myotoxins is the plasma membrane of the muscle fiber. However, the precise
mechanism of action, as well as the mechanism of the toxin's selectivity for this
tissue, remains unclear (Lamonte, 1994; Fletcher et al., 1997).
The third group of myotoxins are the hemorrhagic toxins that also have
myotoxic activity (Ownby et al., 1978; Fabiano and Tu, 1981; Queiroz et aI, 1985;
Harris and Cullen, 1990). In this instance, myonecrosis is usually secondary. As






























supplying muscle tissue, the region becomes ischemic, and the muscle cells
begin to die from a lack of oxygen.
The majority of toxins that induce myonecrosis are related to those animal
enzymes that function in digestion, and thus have evolved to be particularly rapid
and devastating in action. For humans, the onset of myotoxicity can occur so
quickly that even the administration of antivenin minutes after envenomation will
do little in the prevention of local tissue damage (Reid et al., 1963). This type of
damage can lead to loss of fingers, toes and other extremities (Tu, 1991). For
small prey animals, the myotoxic components attack the major organs systems
as well, leading to death due to internal digestion (Tu and Homma, 1970).
Hemorrhagic Action of Snake Venom
Another striking feature of local tissue damage is that of hemorrhage, or
the rupture of vascular endothelial cells. Hemorrhagic toxins are common to the
venoms of Viperidae and Crotalinae, and a venom may contain more than one
(Tu, 1991). Hemorrhagic toxins are not specific for those families, however, as
Ophiophagus hannah of the Elapids contains a species specific toxin
(Weissenberg et al., 1987). Hemorrhagic toxins are all, to some degree,
proteases (zinc metalloproteinases) ranging from 25 kDa to 90 kDa in molecular
weight. The larger hemorrhagic proteins generally tend to be more active in vivo
(Bjarnason and Fox, 1988) due to the presence of a disintegrin domain (Hite et
al., 1992). Disintegrins are low-molecular weight peptides that can inhibit platelet
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aggregation. It is known that the basal lamina of capillaries is often disrupted by
hemorrhagic toxins (Ownby et a/., 1978), and it is hypothesized that the
disintegrin domain targets the integrins of the vascular endothelia (Takeya et al.,
1990).
The effects of hemorrhagic toxins occur much faster than those of
myotoxins (Tu, 1991), but the details of their mechanism of action are still
incomplete. One theory indicates that small breaks in the basal lamina induced
by the toxins stimulates an endogenous action that then rapidly degrades the
endothelium (Lomonte, 1994). By whatever process the vessel breaks, there are
two methods in which the erythrocytes escape. Interestingly, these processes
may be toxin specific, too. Hemorrhage per diapedesis occurs when red blood
cells exit the vessel through enlarged intercellular junctions of the endothelial
cells (Ownby, 1990). A toxin isolated from the venom of Trimeresurus f1avoviridis
was shown to induce hemorrhage of this type (Oshaka et al., 1975).
Hemorrhage per rhexis occurs as erthyrocytes escape the vessel through true
transcellular gaps within a damaged endothelial cell (Ownby, 1990). Several
toxins purified from the venoms of a number of Crotalids caused red blood cell
extravasation per rhexis (Ownby et al., 1978; Ownby, 1990).
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Other Components of Snake Venom
In addition to the potent neurotoxins, myotoxins and hemorrhagk toxins,
snake venoms also contain a number of relatively non-toxic components. About
90% of snake venom components are proteins, but only a relatively small
number of these are the active toxins. Hyaluronidase, of course, and serotonin
are present. These are responsible for "spreading" and pain, respectively.
Rattlesnake venom also contains a bradykinin-releasing factor that is not
common to Hydrophiidae or Elapidae. Small amounts of free amino acids and
glycoproteins are typically common to all species. All of these "non-toxic"
components are typically synergistic, in that they help increase a venom's overall
toxicity. This is particularly true of rattlesnake venom, in which the whole venom
is more toxic than the individual toxins alone (Tu, 1982).
Venoms of Agkistrodon contortrix laticinctus and Crotalus viridis viridis
The venoms of Agkistrodon contortrix laticinctus (ACL) and Crotalus
viridis viridis (CVV) were chosen for this experiment not only for their availability
but as representative examples of Crotalid venom. The venom of both species
induce the types of local tissue damage investigated in this study, i.e., edema.
hemorrhage and myonecrosis. Additionally, apart from the fact that they
represent two different genera, it is suggested that the two venoms have slightly
different characteristic hemorrhagic and myotoxic actions.
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Myotoxicity induced by Crotalus viridis viridis (CVV) and Agkistrodon
contortrix laticinctus (ACL) venoms is in part a result of phospholipase-A2
myotoxins (Johnson and Ownby, 1993a; Ownby et al., 1997). The specific
myotoxic protein from CVV venom (D49·PLA2) is basic, approximately 14 kDa,
and has high catalytic activity on artificial substrates (Ownby et al., 1997). The
myotoxic molecule of ACL venom (K49-PLA2), while having the PLA2 structure
(Araujo et a/., 1996), has little or no enzymatic activity due to a substitution of
lysine for aspartic acid at position 49 (Johnson and Ownby, 1993a; Araujo et al.,
1996). Both of these PLA2 toxins induce a rapid myonecrosis which is identical
to that seen with the crude venoms (Mebs and Ownby, 1990; Fletcher et al.,
1997).
Hemorrhage induced by Agkistrodon contortrix laticinctus (ACL) and
Crotalus viridis viridis (CVV) venoms is in part a result of metal-dependent
metalloproteinases. These enzymes, mostly zinc-dependent, show activity
towards substrates such as casein and collagen and range in size from 22,000
Da to 100,000 Da (Bjarnason and Fox, 1988). Johnson and Ownby (1993b)
isolated a hemorrhagic toxin, ACL hemorrhagic toxin I, from the venom of the
Broad-banded Copperhead that has a molecular weight of about 29,000 Da. It is
similar in behavior to other hemorrhagic toxins found in other venoms, as it
shows enzymatic activity towards protease substrate and can be inhibited by
EDTA, suggesting that it is a metalloproteinase. Li et al. (1993) isolated two
high-molecular weight hemorrhagic toxins from the venom of C. viridis viridis,
both of which are metalloproteinases and are proteolytic on such substrates as
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N,N-dimethylcasein and fibrinogen. One of the toxins has a molecular weight of
68,000 (pI of 8.5) and the other toxin has a weight of 62,000 (pI of 4.1). Based
of behavior and molecular weights, the two toxins are reported to be similar to
another hemorrhagic toxin in CVV venom, viriditoxin (Gleason et al., 1983).
Viriditoxin, a high-molecular weight hemorrhagic toxin, first reported by Fabiano
and Tu (1981), consists of two protein subunits of molecular weights of 57,000
and 62,000. These two toxins differ from ACL hemorrhagic toxin I in that they
both digest the Au-chain of fibrinogen without hydrolyzing the Br> chain, while the
ACL toxin digests both fibrinogen chains. The two CVV toxins differ from each
other in that the 62,000 mol. wt. toxin lost its activity when its sugar moiety was
oxidized, but the 68,000 wt. toxin retained hemorrhagic ability (Li et al., 1993).
The edema-forming activity of ACL and CVV is not well documented and
is a major purpose of the proposed research. However, since PLA2 toxins from
Bothrops asper (Lomonte and Gutierrez, 1989), Trimeresurus mucrosquamatous
(Liu et al., 1991) and Bothrops schlegelii (Angulo et al., 1997) venoms have been
reported to induce edema, it is likely that both the ACL and CVV myotoxins







Venoms of the Broad-banded Copperhead (Agkistrodon contortrix
laticinctus) and the Prairie Rattlesnake (Crotalus viridis viridis), like other Crotalid
venoms, cause severe local tissue damage such as edema, hemorrhage and
myonecrosis (Ownby, 1990). Antivenom (Ax), though generally effective at
reducing systemic signs related to mortality, is rather ineffective at reducing
morbidity unless incubated with the venom prior to injection (Russell, 1973) and
has been shown to be ineffective in neutralization of the effects of CVV venom
(Ownby and Colberg, 1987). Such observations support the need for an effective
first-aid regimen aimed at minimizing local tissue reactions. Some of the
myotoxic activity of these venoms is due to phospholipase A2 toxins, such as
ACL myotoxin (Johnson and Ownby, 1993a) and CVV myotoxin (Ownby et al.,
1997). Since para-bromophenacyl bromide, an inhibitor of the PLA2 catalytic
activity, has been shown to inhibit the myotoxic action of these two PLA2
myotoxins, we hypothesized that this compound would inhibit part of the
myotoxic activity of these crude venoms. Initially, the venoms were mixed with
either p-BPB or Ax prior to injection. Later, the venoms were mixed with both p-
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BPB and Ax prior to injection into the muscles of the lower hindlimb of mice.
These tests were performed to measure the in vitro neutralization capacity of the
antagonists for ACL and CVV venoms. In tests to determine the in vivo
neutralization ability of the antagonists, mice were injected with venom followed
by either topical DMSO containing p-BPB or injected i.m. with saline containing
p-BPB. A final set of mice received the in vivo treatment as described above, but
were followed by i.p. infusions of Ax in order to simulate experimental first-aid,
then hospital treatment. Edema was measured by determining the increase in
diameter of the injected leg; hemorrhage by determining the increase of
hemoglobin in the muscle sample; and myonecrosis by measuring the rise in
creatine kinase levels in the blood. In the in vitro neutralization tests, edema was
significantly reduced when both antagonists were used together, but not with
either alone. p-BPB and Ax tended to increase the hemorrhagic activity of the
ACL venom, but halved the CVV induced hemorrhage. The antagonists showed
a highly significant neutralization of ACt- and CVV-generated myonecrosis when
used individually, and the neutralization was even greater when they were used
together. In the in vivo neutralization experiments, Lp. antivenom significantly
reduced edema, hemorrhage and myonecrosis induced by CVV venom. Other
antagonists induced few statistically significant changes in the parameters
measured. However, hemorrhage was significantly reduced when ACL venom
was followed by topical DMSO-p-BPB. In general, edema tended to increase
with the application of both topical p-BPB in DMSO and Lm. saline containing p-
BPB. Antivenom reduced the myotoxic effect of both venoms, but the other
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antagonists had no effect in vivo, except when ACL venom was foll'owed by i.m.
saline-p-BPB (p<O.1).
Introduction
Venoms of the Broad-banded Copperhead (Agkistrodon contortrix
laticinctis) and the Prairie Rattlesnake (Crotalus viridis viridis) can cause severe
local tissue damage such as edema, hemorrhage and myonecrosis (Ownby,
1982; Ownby and Colberg, 1987, 1988; Johnson and Ownby, 1993a,b).
Antivenom (Ax), though generally effective at reducing systemic signs related to
mortality, is rather ineffective at reducing morbidity unless incubated with the
venom prior to injection (Russell, 1973) and has been shown to be ineffective in
neutralization of the effects of CVV venom (Ownby and Colberg, 1987).
Antivenom has not been shown to be very effective at reducing the local tissue
damage induced by venom, even when administered immediately after
envenomation (Ownby et al., 1983; Lomonte et al., 1993a; Rucavado and
Lamonte, 1996). Such observations support the need for an effective first-aid
regimen aimed at minimizing local tissue reactions. Some of the myotoxic
activity of these venoms is due to phospholipase A2 toxins, such as ACL
myotoxin (Johnson and Ownby, 1993a) and CVV myotoxin (Ownby et al., 1997).
Since para-bromophenacyl bromide, an inhibitor of the PLA2 catalytic activity,
has been shown to inhibit the myotoxic action of these two PLA2 myotoxins, we
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hypothesized that this compound would inhibit part of the myotoxic activity of
these crude venoms.
Phospholipase A2 toxins are responsible for much of Crotalid venom's
myotoxicity (Ownby, 1990; Mebs and Ownby, 1990; Lomonte, 1994), and they
are implicated directly and indirectly in the formation of edema (Lomonte, 1994).
Administration of a chemical agent that is antagonistic to venom phospholipase
A2 could reduce the overall brunt of the venom action, and therefore decrease
the need for extensive therapy at a medical facility. Earlier work by Ownby et al.
(1975) identified a number of substances, namely procaine HCL and chelating
agents like ethylenediaminetetracetic acid (EDTA) and
diethylenetriaminepentacetic acid (DTPA), which antagonized the hemorrhagic
activity of Grotalus atrox venom. Myotoxicity induced by Grotalus viridis viridis
(CVV) and Agkistrodon contortrix laticinctus (ACL) venoms is in part a result of
phospholipase-A2 myotoxins. The specific myotoxin from CVV venom, CVV
myotoxin (D49-PLA2), is basic, about 14 kDa and catalytically active (Ownby et
al., 1997). The myotoxic molecule of ACL venom (K49-PLA2), while having the
PLA2 structure (Araujo et al., 1996), has little or no enzymatic activity due to a
substitution of lysine for aspartic acid at position 49 (Johnson and Ownby,
1993a; Araujo et al., 1996). Ownby et al. (1'997) demonstrated that para-
bromophenacyl bromide, a PLA2 inhibitor that acts by binding to the histidine
residue in the active site of the enzyme (Volwerk et al., 1974), is an effective
antagonist of the myotoxic activity of the myotoxin from Grotalus viridis viridis. p-
BPB also antagonizes the myotoxic activity of ACL myotoxin from Agkistrodon
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contortrix laticinctus in vitro, despite the apparent lack of enzymatic activity (Melo
and Ownby, 1996). In addition to hemorrhage and myonecrosis, edema is a
prominent local effect of many venoms (Ownby, 1990). While the exact methods
of the edema-forming activities are still under investigation, Liu et al. (1991) and
Lomonte and Gutierrez (1989) characterized one PLA2 of A. p. piscivorus and
Bothrops asper, respectively, specifically as "edema inducing." The PLA2
enzymes in the venom can also induce damage to the vascular endothelia
resulting in hemorrhage (Lamonte et aI., 1993b). It is uncertain, however, how
much of a contribution each of the crude venom components plays in the
formation of local tissue damage.
The purpose of this work was to analyze the ability of p-BPB in
combination with antivenom to neutralize the local tissue effects of edema,
hemorrhage and myonecrosis induced by ACL and CVV venoms. Since the
PLA2 myotoxins are responsible for the myotox,ic and edema-forming activities of
the ACL and CVV crude venoms, and these activities are inhibited by p-BPB, it
was hypothesized that the administration of p-BPB following injection of ACL and





Source of A. c. laticinctus and C. v. viddis venoms
Agkistrodon contortrix laticinctus venom was a pool of venom (Lot
#051793) obtained from 15 snakes collected in central Texas, U.S.A., and
maintained at the Venom Research Laboratory Serpentarium, Oklahoma State
University, Stillwater, OK, U.S.A. Crotalus viridis viridis venom was a pool of
venom (Lot #091592) obtained from 13 snakes collected from western
Oklahoma, positively identified as Crotalus viridis viridis using taxonomic criteria,
and maintained in the Venom Research Laboratory Serpentarium, Oklahoma
State University, Stillwater, OK, U.S.A. The venom was extracted by allowing
the snakes to bite through Parafilm® which covered a glass funnel that emptied
into a polycarbonate centrifuge tube resting in an ice bath. Immediately after
extraction the venom was centrifuged at 28,000 x 9 for 20 min using a Sorvall
RCR5 refrigerated centrifuge (4QC) to remove insoluble material, frozen, and
then lyophilized. Lyophilized venom was stored over desiccant a -20QC until




Adult female CD-1 mice (28-30g) were purchased from Charles River
Laboratories, Inc., Wilmington, MA.
Inhibitors/Venom Solutions
The p-BPB was purchased from Sigma Chemical Co., St. Louis, Mo.,
U.S.A. and was used by adding 1mg to 1 ml of the appropriate venom or vehicle
solution (PSS or DMSO gel) according to Ownby et al. (1997). Antivenom was
obtained from Wyeth-Ayerst Laboratories, Mariette, PA, USA. Dimethyl
sulfoxide (DMSO) gel and physiologic saline (PSS) gel were purchased from
FWI, Tulsa, OK, U.S.A. and Baxter Health Care Corporation, Deerfield, IN,
U.S.A., respectively. The DMSO gel was used as a vehicle for transcutaneous
absorption of the p-BPB for methods described later. In the in vitro tests, venom
was reconstituted in either physiologic saline (0.90% NaCI) or Wyeth's Polyvalent
(Crotalidae) antivenom to form the experimental dose concentrations of venom
(2.0I-lg/g for ACL and 1.0I-lg/g for CVV). The antivenom-venom solution was
incubated overnight at 4QC. p-I3PB was added to both the venom and
antivenom:venom solutions to a final concentration of 1 mg/ml for the p-BPB and
incubated overnight at 37QC. In the in vivo tests, p-BPB was mixed in either PSS
or DMSO to a final concentration of 1 mg/ml. Each particular inhibitor solution,
minus the crude venom, was used as a control for each particular




Determination of ED50 dose for Edema. Hemorrhage. Myonecrosis.
To determine the final experimental doses of venom, mice were injected
with logarithmic increments of ACL (0.1. 1.0, and 10.0 Ilg/g) and CVV (0.05, 0.5,
and 5.0 Ilg/g) venom concentrations. Assays measuring the edema,
hemorrhage and myonecrosis (described later) were performed and the dose
approximating the ED50 for each parameter was determined. The criteria used
for selecting the dose of venom were: (1) at least one EDso, (2) dose which
induces measurable local tissue damage, and (3) sub-lethal dose.
Injection Protocol
In vitro neutralization. The venom and antagonist were incubated
together overnight at 37QC. Each mouse was anesthetized with Methoxyflurane,
then the right hindlimb of each mouse was shaved. While under anesthesia, 0.05
ml of the test solution was injected into the dorsolateral aspect of the right
gastrocnemius muscle. At four hours after the injection, each mouse was again
anesthetized and euthanized by cerv'ical dislocation. Then, final measurements
for edema, and blood and muscle samples were taken.
In vivo neutralization. Mice were treated as in the in vitro protocol except
that the venom and antagonist were applied separately. The in vivo treatments
were as follows: (A) 1 minute after injection of the venom solution, 0.05 ml of
90% DMSO gel with or without p-BPB (1 mg/ml) was rubbed onto the site of
injection; (B) 1 minute after injection of the venom solution, 0.05 ml of PSS with
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or without p-BPB (1 mg/ml') was injected into the site of injection. Attempts were
made to use the same hole made by the initial injection of venom to minimize
muscle trauma; (C) protocols A and B were repeated as previously described,
but thirty minutes after the injection of venom and the experimental treatment,
0.25 ml of antivenom was administered i.p. All samples were taken four hours
after injection.
Determination of PLA2 Activity
Phospholipase A2 activity of venom was determined by measuring the
release of free fatty acid from a solution of L-1-phosphatidylcholine resulting in a
lessening of coloration as shown by the pH indicating dye, cresol red, at 578nm.
All reagents for this assay were purchased from Sigma Chemical Co. (S1. Louis,
Mo., USA). Four solutions were required for the assay: (1) L-1-
phosphatidylcholine solution, made by dissolving 1 gram of phosphatidylcholine
with 10ml Methanol and 3ml Triton X-100 and bringing to 20ml with dH20; {2)
Indicator solution, made by combining 1.5 mg cresol red and 250/l1 Methanol and
bringing to 25ml with dH20; (3) Glycylglycine solution (0.10M), made by
combining 330mg glycylglycine with 25ml dH20; and (4) Calcium chloride
solution (90mM), made by combining 200mg calcium chloride with 20ml dH20.
The buffered substrate solution (8SS) was made by combining 4ml of (1), 7ml of
(2), 3ml of (3), 1ml of (4) and 10ml of dH20. The pH of the solution was adjusted




Test samples of the various venom and venom:antagonist solutions were
prepared as described above in Inhibitors. A 1ml semi-micro quartz cuvette was
put into a Beckman DU-8 spectrophotometer (Beckman Instruments. Inc.,
Fullerton, CA) and the absorbance was zeroed at 578nm, then one ml of BSS
was put into the cuvette, and the absorbance was recorded. With one hand,
10ul of sample was put into the cuvette containing BSS. and the solution was
immediately mixed with a Pasteur pipette held in the other hand. Absorbance
was recorded at one minute after the addition of the sample. The extinction
coefficient (e) was determined by recording the Abs 578 of the Buffered saline
solution (BSS) and again recording the Abs 578 one minute after adding 1O~I of
0.1 N HCL. The Volume Activity (U/ml) of venom fractions was determined using
the formula (1.01 * E/0.01 *e) where E is the change in Absorbance per minute
and e is the extinction coefficient. The Specific Activity was determined by
dividing the Volume Activity (U/ml) by the sample concentration.
Determination of Edema
With mice under anesthesia, the pre-injection diameter of the lower
hindlimb was measured using low-pressure spring calipers. Four hours after the
injection, the mouse was euthanized by cervical dislocation and the increase in
muscle thickness was measured. Edema was expressed as the percent (%)




The hemorrhage assay was performed as described in Ownby et al.
(1984), with a few modifcations. After the allotted four hour time period, the test
mice were euthanized by cervical dislocation. The skin was removed from the
site of injection (right hindlimb), and the injected muscle was removed. Each
muscle sample was weighed, placed in a test tube, and stored overnight at -200
C until used. For the assay, samples were removed from the freezer and
homogenized in 3 ml of distilled water for 30 seconds using a Brinkmann
Polytron PT (Brinkmann Instruments, Westbury, NY) at a setting of 5. The
homogenates were then centrifuged in an Eppendorf centrifuge for 10 minutes at
5000 rpm. The supernatant between the precipitate on the bottom and foam-like
layer on the top was removed and centrifuged in a Sorvall RC2B refrigerated
centrifuge at 18,500 rpm for 45 minutes. Centrifugation of less than 30 minutes
was not sufficient to dear the supernatant. This supernatant was carefully
removed so as not to disturb the overlying lipid layer and returned to the Sorvall
centrifuge at 18,500 rev/min for another twenty minutes. Then, 1800~1 of the
final supernatant was again carefully removed. The amount of hemoglobin in the
supernatant was measured by the cyanomethemoglobin method, as described in
Sigma Technical Bulletin No. 525, with the following modifications. Drabkins
reagent was mixed at twice normal strength (1 vial + 500 ml dH20), as described
in Ownby et al. (1984), and standards were mixed using the twice normal
strength Drabkins, and 1800~1 of supernatant from homogenized muscle was
added to 5ml Drabkins reagent. Then, 20/11 aliquots were placed in a 96 well
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plate and the absorbance at 520nm was determined using a THERMOmax™
microplate reader (Molecular Devices), and the grams per 100 ml (g%) of
hemoglobin was obtained from a standard curve. A standard curve was
obtained each time using lyophilized human methemoglobin. The g%
hemoglobin was corrected for weight of muscle sample by dividing by the weight
of the muscle.
Determination of Myonecrosis
Myonecrosis was evaluated by quantification of serum creatine kinase
(CK) using a Sigma Creatine Phosphokinase assay (Sigma No. 520). Four
hours after an i.m. injection (in the right gastrocnemius) while under anesthesia,
blood was collected into non-heparinized capillary tubes from the infraorbital
plexus and immediately spun in a hematocrit centrifuge to separate the serum
and erythrocytes. For the assay, 1oIII of serum was added to 0.5 ml
phosphocreatine solution in a 10 ml glass test tube and placed in a water bath at
3rC. Then, 0.2 ml of ADP-Glutathione were immediately added to the serum
solution and allowed to incubate for exactly 30 minutes. After 30 minutes, 0.2 ml
p-hydroxymercurobenzoate was added to stop the reaction. The test tube was
removed from the water bath and 1 ml u-napthol solution, 1 ml diacetyl solution
and 7 ml dH20 were added. The tube was returned to the water bath for another
15 minutes. Separate solutions for a standard curve were made by adding 0,
0.2, 0.4, 0.6, 0.8 and 1 ml of creatine standard solution (Sigma No. 520-C) to the
u-napthol, diacetyl and dH20 solution. Next, 0.2 ml of the standard and test
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solutions were transferred to a 96 well ELISA plate and the absorbance read at
520 nm. Serum [CK] was determined from the standard curve. Results were





Determination of EDso venom dose for Edema, Hemorrhage and Myonecrosis.
The EDso values for each of the local tissue damage parameters generally
occurred within the same range for the respective venoms. Figures 1 and 2
show the results of the dose/response experiments for both venoms for edema,
hemorrhage and myonecrosis. Final experimental doses of 2.0~g/g for ACL and
1.0~g/g for CVV were chosen as these values approximated an EDso for each of
the experimental assays, were less than the LDso and induced measurable
edema, hemorrhage and myonecrosis.
In vitro neutralization
When mice were injected with either ACL or CVV venom that was
incubated with the antagonists, overall local tissue damage was significantly
reduced (p < 0.05) when compared to the venom alone using the Student's t-
test. Venom solutions that were incubated with both p-BPB and antivenom
showed greater reduction of edema, hemorrhage and myonecrosis than
solutions that contained only one antagonist. Figure 3 shows that edema
induced by either venom was only slightly inhibited when the antagonists were
used separately, but edema induced by ACt venom and CVV venom was
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reduced by about 85 and 90 percent, respectively, when the antagonists were
used in combination. Edema induced by CVV venom was also significantly
reduced when combined in vitro with only antivenom. Figure 4 demonstrates
that hemorrhage induced by ACL or CVV venom was reduced by about 50
percent regardless of the antagonist combination. Figure 5 shows that both p-
BPS and antivenom reduced myonecrosis induced by both venoms when used
alone, but neutralized the myotoxicity induced by the ACL and CVV venoms by
85 to 90% when used in combination. Also, p-BPB was more effective than
antivenom in reducing myonecrosis induced by ACL venom, but antivenom was
more effective for CVV venom.
In vivo neutralization
Topical
In general, mice that were injected with either ACl or CVV venom, and
then treated topically with either DMSO gel alone or DMSO gel containing para-
bromophenacyl bromide, showed no reduction of local tissue damage. In fact,
Figure 6 shows a significant increase in edema in mice treated with DMSO or
DMSO-p-BPB following injection of ACL venom and DMSO-p-BPB following
injection of CVV venom. Figure 7 shows that in most cases there was no
significant change in hemorrhagic activity for the treated mice compared to
venom alone, except for a single significant reduction of hemorrhagic activity
when mice injected with ACL venom were treated with DMSO containing p-BPB.
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Figure 8 shows that there was no significant change in myonecrosis between the
mice injected with either venom alone, and those that recieved any antagonist
alone or in combination.
Intramuscular
In general, mice that were injected with either ACL or CVV venom, and
then injected with either saline or saline containing p-SPS, showed no
appreciable change in local tissue damage when compared to venom alone.
Figure 9 shows that a significant increase in edema occurred when an injection
of ACL venom was followed by an injection of saline. Figure 10 shows that the
only significant change was an increase in hemorrhagic activity when an injection
of ACL venom was followed by an injection of saline containing p-BPS. Figure
11 records that no significant change in myonecrosis occurred between groups
receiving either venom alone or venom followed by i.m. saline or saline with p-
BPS at a significance level of p < 0.05. Myonecrosis induced by ACL venom
after i.m. saline-p-BPB was reduced, but at a significance level of p < 0.1.
Antivenom
80th the topical and i.m. treatments followed by i.p. injections of
antivenom 30 minutes after venom showed few significant reductions of local
tissue damage parameters. In fact, most significant changes were positive.
Figure 12 shows a significant increase in edema with all treatments following
injection of ACL venom when compared to the value for venom alone or venom
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followed by antivenom. Mice receiving antivenom alone and mice receiving
saline-p-BPB following injections of CVV venom demonstrated a significant
reduction in edema when compared to CVV venom alone.
Figure 13 shows that the only significant reduction in hemorrhage was
obtained for CVV venom followed by antivenom alone or by i.m. saline-p-BPB
and antivenom. All other significant changes were increases.
Figure 14 shows a significant decrease in myonecrosis in mice receiving
antivenom, DMSO-p-BPB and saline-p-BPB treatments following injections of
CVV venom alone. ACL- induced myonecrosis was also reduced by i.p.
antivenom compared to venom alone, but only at a significance level of p < 0.1.
Figure 14 also demonstrates that there was no significant changes in myotoxicity
when venoms were followed by topical treatment, then antivenom, when
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Figure 1. Dose-response relation of local tissue damage parameters
following injection of ACL venom at 0.1, 1.0 and 10.0 ,ug/g. Edema is
measured in % increase in diameter; Hemorrhage is measured in g% [Hb]
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Figure 2. Dose-response relation of local tissue damage parameters
following injections of CVV venom at 0.05, 0.5, and 5.0 119/9. Edema is
measured in % increase in diameter; Hemorrhage is measured in g% [Hb]





















































Figure 3: In vitro neutralization of edema induced by ACL and CVV
venoms. PSS = 0.90% NaCI; ACL = A. contortrix laticinctus venom
(2.0~g/g); CVV = C. viridis viridis venom (1.0119/9); pBPB = para-
bromophenacyl bromide; Ax = Wyeth's Polyvalent (Crotalidae) Antivenin.
Bars represent mean :: S.~.M. (n = 4). ... Indicates damage level






















Figure 4: In vitro neutralization of hemorrhage induced by ACL and CVV
venoms. PSS = 0.90% NaCI; ACL = A. contortrix laticinctus venom
(2.0I-1g/g); CVV = C. viridis viridis venom (1.0I-1g/g); pBPB = para-
bromophenacyl bromide; Ax = Wyeth's Polyvalent (Crotalidae) Antivenom.
Bars represent mean ± S.E.M. (n = 4). "Indicates damage level































In vitro nelJtralization of myonecrosis induced by ACL and
CVV venoms. PSS = 0.90% NaCl; ACL = A. contortrix laticinctus venom
(2.0y.g/g); CVV = C. viridis viridis venom (1.0119/9); pBPB = para-
bromophenacyl bromide; Ax =Wyeth's Polyvalent (Crotalidae) Antivenom.
Bars represent mean± S.E.M. (n = 4). "Indicates damage level
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Figure 6: In vivo edema induced by ACL and CVV venoms followed by
topical DMSO, with or without pBPB, PSS =0.90% NaCl; ACL (A) =A.
contortrix Jaticinctus venom (2.01-1g/g); CVV (C) = C. viridis viridis venom
(1.0~g/g); 0 =OMSO; P =para-bromophenacyl bromide. Bars represent
mean ± S.E.M. (n = 6). ~ Indicates damage level signif.icantly different at























Figure 7: In vivo hemorrhage induced by AGL and GVV venoms
followed by topical DMSO, with or without pBPS. PSS = 0.90% NaGI;
AGL (A) = A. contortrix laticinctus venom (2.0~g/g); GVV (G) = C. viridis
viridis venom (1.0!-1g/g); 0 = DMSO; P = para-bromophenacyl bromide.
Bars represent mean :: S.E.M. (n = 6). "Indicates damage level



























Figure 8: In vivo myonecrosls induced by ACL and CVV venoms
followed by topical DMSO, with or without pBPB. PSS = 0.90% NaCI;
ACL (A) = A. contortrix laticinctus venom (2.0!-l9/g); CVV (C) = C. viridis
viridis venom (1.0fi9/9); 0 = DMSO; P = para-bromophenacyj bromide.
Bars represent mean ± S.E.M. (n = 6). * Indicates damage level




























In vivo edema induced by ACL and CVV venoms followed by
I.M. injection of PSS with or without pBPB. PSS =0.90% NaGl; AGL (A) =
A. contortrix laticmctus venom (2.0ug/g); CVV (G) = C. viridis viridis venom
(1.0!lg/g); pBPB = para-bromophenacyl bromide. Bars represent mean::!:
S.E.M. (n =6). "Indicates damage level significantly different at p < 0.05


















Figure 10: In VIVO hemorrhage induced by ACL and CVV venoms
followed by I.M. injection of PSS with or without pBPB. PSS = 0.90%
NaCI; ACL (A) = A. contortrix laticinctus venom (2.0~g/g); CVV (C) = C.
viridis viridis venom (1.0!-J.g/g); pBPS = para-bromophenacyl bromide.
Bars represent mean± S.E.M. (n = 6). * Indicates damage level
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Figure 11: In vivo myonecrosls induced by ACL and CVV venoms
followed by !.M. injection of PSS with or without pBPB. PSS = 0.90%
NaCI; ACL (A) = A. contortrix laticinctus venom (2.0)1g/g); CVV (C) = C.
viridis viridis venom (1.0)lglg); P = para-bromophenacyl bromide. Bars
represent mean:: S.E.M. (n = 6). * Indicates damage level significantly
different at p < 0.05 when compared to venom alone using Student's t-
test. U Indicates damage level significantly different at p < 0.1 when
compared to venom alone using Student's t-test.
63
)( '" )( )(en -= ::. ::.



































'.J x x. x. x- -= ~ ::.




Figure 12: In vivo edema induced by ACL and CVV venoms following
topical and i.m. treatments and i.p. infusions of antivenom. pss = 0.90%
NaCI; a = A. contortrix laticinctus venom (2.0!l9/g); c = C. viridis viridis
venom (1.0,Llg/g); d = DMSO; p = para-bromophenacyl bromide (1 mg/ml);
x = Wyeth's Polyvalent (Crotalidae) Antivenom. Bars represent mean ~
S.E.M. (n = 6). "Indicates damage level significantly different at p < 0.05
when compared to venom alone using Student's test. *** Indicates
damage level significantly different at p < 0.05 when compared to venom
























Figure 13: In vivo hemorrhage induced by ACL and CVV venoms
following topical and i.m. treatments and i.p. infusions of antivenom. pss =
0.90% NaCI; a = A. contortrix laticinctus venom (2.0!lg/g); c = C. viridis
viridis venom (1.0!l9/g); d = DMSO; p = para-bromophenacyl bromide
(1 mglml); x = WyethJs Polyvalent (Crotalidae) Antivenom. Bars represent
mean ± S.E.M. (n =6). "Indicates damage level significantly different at p
< 0.05 when compared to venom alone using Student's t-test.
**"Indicates damage level significantly different at p < 0.05 when
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Figure 14: In vivo myonecrosis induced by ACL and CVV venoms
following topical and i.m. treatments and i.p. infusions of antivenom. pss = 0.90%
NaCI; a = A. contortrix laticinctus venom (2.0I-lg/g); c = C. viridis viridis ven·om
(1.0~g/g); d = DMSO; P = para-bromophenacyl bromide (1 mg/ml); x = Wyeth's
Polyvalent (Crotalidae) Antivenom. Bars represent mean == S.E.M. (n = 6). ..
Indicates damage level significantly different at p < 0.05 when compared to
venom alone using Student's t-test...... Indicates damage level significantly
different at p < 0.1 when compared to venom alone using Student's t-test. ..... "
Indicates damage level significantly different at p < 0.05 when compared to





Edema, hemorrhage and myonecrosis are common results of Crotalid
envenomation and are often implicated in venomous encounters with the prairie
rattlesnake (Crotalus viridis viridis) and the broad-banded copperhead
(Agkistrodon contortrix laticinctus). The present study has shown that in
comparing the venoms of Crotalus viridis viridis (CVV) and Agkistrodon contortrix
laticinctus (ACL), the rattlesnake venom is more hemorrhagic than the
copperhead venom, as the CVV venom induced 4 to 5 times the hemorrhage of
ACL venom despite being administered at half the dose of ACL venom. Several
hemorrhagic toxins have been identified in CVV venom including viriditoxin,
(Fabiano and Tu, 1981) and two other high-molecular weight, 62 and 68 kDa,
hemorrhagic toxins (Li et aI., 1993). A low-molecular weight hemorrhagic toxin
has been isolated from ACL venom, ACL hemorrhagic toxin I, but it is not
responsible for all of the hemorrhagic activity as the crude venom demonstrated
more activity than the purified hemorrhagic toxin alone (Johnson and Ownby,
1993b). The presence of more high-molecular weight hemorrhagic toxins in the
CVV venom may account for the results of the present experiment, as the
higher molecular weight hemorrhagic toxins are generally more potent
(Bjarnason and Fox, 1994). The results of the hemorrhage assays in this
experiment are consistent with Ownby et al. (1988), who reported massive
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hemorrhage as a result of CVV envenomation. Taking into account the
difference in the experimental doses for ACL and CVV venom, both venoms
caused about the same degree of myotoxicity. Both ACL and CVV venom have
been shown to contain potent PLA2 myotoxins, ACL myotoxin (Johnson and
Ownby, 1993a; Melo and Ownby, 1996) and CVV myotoxin (Ownby et al., 1997),
respectively. In general, CVV venom also tended to generate more edema than
ACL venom. The presence of toxins in ACL and CVV venoms that are directly
responsible for edema formation have yet to be determined, but the increased
hemorrhagic activity of CVV venom compared to ACL venom may explain some
of the greater amount of swelling induced by CVV venom. It should be noted that
the gross appearance of edema seen in this experiment was different for the two
venoms. ACL-induced edema appeared as a "puffy," serous-filled expansion of
the limb that could be collapsed by slight pressure whereas, CVV-induced
edema was not only sera-sanguinous, but also indurated, and could not be
compressed by pressure. The type of edema produced by CVV venom is quite
possibly related to this venom's increased hemorrhagic activity. Another
possible explanation for the different manifestations of edema is the presence of
different variants of PLA2 myotoxins in the two venoms. ACL myotoxin in ACL
venom is enzymatically inactive, or shows very little enzymatic activity (Johnson
and Ownby, 1993a) while CVV myotoxin in CVV venom is catalytically active
(Ownby et al., 1997). Liu et al. (1991), Lomonte et al. (1993b), and Angulo et al.
(1997) reported that PLA2 myotoxins fram the venoms of T. mucrosquamatus, B.
asper and B. schlegelii, respectively, can cause the formation of edema, and that
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these toxins are K-49, or lysine-49 PLA2 variants, the same as ACL myotoxin
(Johnson and Ownby, 1993a). CVV myotoxin is a 049, or aspartate-49 PLA2
(Ownby et al., 1997). The role of PLA2s, and the presence or absence of
catalytic activity, in edema-formation following envenomation is still controversial
(L1oret and Moreno, 1993).
The present study also shows that samples for quantitating local tissue
damage such as edema, hemorrhage and myonecrosis can be taken from the
same animal, thus facilitating comparisons of these effects and their
neutralization. Hemorrhage and myonecrosis were determined by measuring the
g% hemoglobin concentration of the affected muscle sample (Ownby et al.,
1984) and the rate of release of CK from the envenomated muscle (Ownby et al.,
1997), respectively. Edema was based on the relative increase in diameter of
the envenomated lower hindlimb, similar to the measurements of the footpad, as
described by Lomonte et al. (1993a). Usually, hemorrhage is measured using
Kondo's method (Kondo et al., 1960) which requires an i.d. injection, not an Lm.
injection as was done here. Although there are criticisms of measuring the
extent of myonecrosis using the CK assay technique, Lomonte (1994) found that
despite the number of alternative causes of elevated CK levels in serum, there is
a dose-response correlation between venom-induced myonecrosis and CK
levels. Ownby et al. (1982) compared CK assay and histological evaluation
methods for measuring myonecrosis and found a highly significant correlation
between these different assays at times of at least 3 hours after injection of
venom. Initial increases in CK are due to muscle contraction, but CK release
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from muscle cells three hours post-injection of CVV venom is related to
increases in permeability of the sarcolemma, which directly precedes vacuolation
(Ownby et al., 1976).
The final experimental doses for ACL (2.0J-tg/g) and CVV (1.0J-tg/g) venom
were chosen from the inibal dose-response experiments not only because they
approximated EDso responses for each of the local tissue damage parameters
but also because these doses are sub-lethal. Khole (1991) lists the Lm. LDso of
ACL venom to be 20 ~Lg/g and Ownby et at. (1985) lists the i.m. LDso of CVV
venom to be 3.0 ~Lg/g. It was important to use venom doses that were high
enough to induce measurable edema, hemorrhage and myonecrosis, but still
sub-lethal to correlate with the dose of venom injected in an actual snakebite.
These final venom doses also induced levels of experimental tissue damage
sufficient to allow neutralization to be detected, as indicated by the values
obtained for edema, hemorrhage and myonecrosis in the Results Section.
In general, the combination of the antagonists, p-BPB and Ax, with venom
prior to injection resulted in significant reductions in edema, hemorrhage and
myonecrosis for both venoms. Venom solutions that contained both p-BPB and
antivenom showed a greater reduction of edema than when only one of the
antagonist was incubated with the venom. Lack of reduction of edema in vitro by
p-BPB alone may indicate that PLA2s play only a minor role in direct edema
formation. Since antivenom has been shown to reduce the edema-forming
activity of B. aspervenom (Lamonte, 1993a), a closely related snake, antivenom
may be responsible for most of the reduction observed with ACL and CVV
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venoms in the present study. Comparison of the results with the two venoms, in
vitro, may also indicate that more than one type of toxin present in the venom is
responsible for edema formation. That is, since hemorrhagic toxins affect the
integrity of the capillary wall, which promotes the leakage of fluids into the
extravascular space, they could also be indirectly responsible for subsequent
edema. ACL and CVV contain hemorrhagic toxins (Johnson and Ownby, 1993b;
Li et al., 1993) which are highly immunogenic (Ownby and Colberg 1987; Li and
Ownby, 1996), and it has been shown that antivenom does have a high affinity
for high molecular weight proteins, such as hemorrhagic toxins (Li and Ownby,
1996). The ability of antivenom to reduce edema could indicate that it is the
hemorrhagic toxins producing the bulk of the edema. The increased reduction of
edema seen when venom was mixed with both antivenom and p-BPB as
compared to either antagonist alone could indicate that the inhibitors are
neutralizing different venom components responsible for hemorrhage. However,
since the reduction is more than additive, i.e., edema induced by either venom is
reduced by about 70 percent when combined with both inhibitors, whereas
reduction of edema caused by either venom is at best about 30 percent when
mixed with only one of the antagonists, it is possible that the presence of p-BPB
in the antivenom solution potentiates the neutralization by some other secondary
factor such as a change in pH or an alteration in the structure of other venom
components that makes them more susceptible to antivenom binding. Additional
studies are needed to investigate this possibility.
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The ability of both p-BPB and antivenom to equally reduce hemorrhage
induced by both venoms in vitro raises some interesting questions about the
involvement of PLA2s in hemorrhage. It has been shown that hemorrhage is
primarily the result of metalloproteinases (Bjarnason and Fox, 1988;1994). Both
CVV (Li et al., 1993) and ACL (Johnson and Ownby, 1993b) contain these
hemorrhagic toxins. However, nothing is known about the ability of p-BPB to
inhibit such metalloproteinases. Perhaps the inhibition is due to a secondary
effect such as a change in pH of the solution. Further experiments need to be
done to determine the cause of this inhibition. It is possible that the PlA2s are
rupturing endothelial cell membranes as well as muscle cell membranes. In fact,
Lamonte et al. (1994) showed that a PLA2 myotoxin from B. asper venom
damages endothelial cells in culture. It might be assumed that if the p-BPB was
only neutralizing the PLA2-induced hemorrhage, that the response of the Ax
treated venom would be lower due to the inhibition of hemorrhagic toxins.
However, since there is no difference in the reduction of hemorrhage between
the two treatments, the question of whether or not the antagonist are
"antagonizing" the same components is raised. It would be interesting to test p-
BPB's ability to neutralize purified hemorrhagic toxins from these venoms.
All treatments showed a significant reduction in myonecrosis when p-BPB
and Ax were individually mixed with the venom prior to injection, but tests
showed even greater neutralization when the two antagonists were used in
combination. The reduction of myonecrosis in the p-BPB treatment indicates that
PLA2 myotoxins from both venoms were neutralized. The lack of total
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neutralization of myonecrosis indicates that there are other non-PLA2 toxins
present ,in these crude venoms that are responsible for muscle damage, such as
myotoxin a in CVV venom (Ownby et al., 1976). The results also demonstrate
that some of the venom components are not neutralized by commercial
antivenom. Ownby et al. (1983;1985) showed that Wyeth's Polyvalent
(Crotalidae) antivenom did not neutralize myonecrosis induced by myotoxin a
from CVV venom, nor does the antivenom have antibodies to myotoxin a (Ownby
et al., 1983). Interestingly, Ownby et al. (1986) found that antimyotoxin a serum
neutralized more myonecrosis induced by CVV crude venom than the
commercial polyvalent antivenom. The previous results are supported by the
further reduction of myonecrosis when venom was treated with p-BPB and Ax
found in the present study. Thus, Wyeth's Polyvalent (Crotalidae) antivenom is
perhaps inhibiting other toxins not inhibited by p-BPB. It could be that the
commercial polyvalent antivenom is reducing myonecrosis caused by vascular
damage and subsequent ischemia, by antagonizing the hemorrhagic toxins.
Ownby et al. (1988) indicated that a large portion of the myonecrosis induced by
CVV venom was a result of hemorrhage and subsequent ischemia.
In general, with the exception of mice receiving i.p. infusions of
antivenom, those mice getting injections of venom followed by topical or i.m.
DMSO-p-BPB or saline-p-BPB, respectively, showed no significant reductions in
local tissue damage. However, hemorrhage induced by ACL venom was
significantly reduced in vivo by topical DMSO-p-BPB. This result is consistent
with the results from the in vitro tests with the same antagonist. It is possible that
the p-BPB is inhibiting hemorrhage induced by the PLA2 activity of ACL venom.
However, the increase in hemorrhage as a result of saline-p-BPB treatment
following injection of ACL venom points again to the caustic nature of the p-BPB
suspension versus the p-BPB solution.
Both the DMSO-p-BPB and saline-p-BPB treatments failed to show any
reduction in the edema-forming activity of the venom. This lack of inhibition is
probably due to the inability of the antagonist to the reach the venom, in vivo, or
to reverse already existing edema. The significant rises in edema seen in the
DMSO treatments are most likely due to the increased spread of the venom
associated with the increased vascular permeability caused by the DMSO itself.
The effectiveness of DMSO to reduce local tissue damage, especially
hemorrhage, is contradictory. Tu et a/. (1970) and Ownby et a/. (1975) reported
DMSO itself to be effective at neutralizing Crotalid induced hemorrhage in vitro
but not in vivo. In the present study, it was used for its action as a
transcutaneous vehicle for p-BPB, with the hope that it would transport more
antagonist than venom. The adverse effects of DMSO have been previously
described in Tu et aJ. (1970). As these previous experiments reported the
inability of DMSO to inhibit hemorrhage in vivo, it is not known which
hemorrhagic components of venom the DMSO is affecting in in vitro
experiments. Further experiments that test the in vitro capacity of DMSO alone
to neutralize venom PLA2s need to be performed. The increases in edema with
saline-p-BPB treatment are possibly a result of the fact that the injected fluid in
this case was, in fact, a suspension and not a solution. p-BPB is not readily
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soluble in saline. It is possible that the non-dissolved p-BPB p'articles were
inducing an inflammatory response themselves.
The inability of any topical or i.m. treatment to reduce myonecrosis
induced by myotoxins may be primarily a problem of time, as the venoms
produce almost immediate muscle damage upon injection. Johnson and Ownby
(1993a) showed that ACL myotoxin injected i.m. induced rapid myonecrosis of
murine muscle cells appearing within 15 minutes. Ownby et al. (1997) also
noted that CVV myotoxin produces rapid onset of myonecrosis, with lesions
appearing within three hours. However, both ACL and CVV myotoxins induce
myonecrosis within 5 minutes of injection (Ownby, personal communication).
The myonecrosis due to myotoxin a is measured in hours, not minutes, as with
the PLA2 myotoxins (Melo and Ownby, 1996). Lomonte et al. (1993b) also
showed that myonecrosis induced by the PLA2 myotoxin from B. asper, Myotoxin
II, was seen only 3 to 4 minutes after application. Apparently, the topical
DMSO-p-BPB or saline-p-BPB cannot reach the site fast enough to prevent
damage.
The concept of a time variable might also factor into the ability of p-BPB to
neutralize some PLA2-induced hemorrhage because of the idea that the PLA2
myotoxins probably do not directly bind to endothelial cells via receptors, but
rather indirectly hydrolyze the plasma membrane of vessel walls. This indirect
process probably takes more time than direct ligand binding reactions. However,
Lamonte et al. (1993b) reported that the PLA2 myotoxin from B. asper venom
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caused extensive plasma leakage from capillaries within 5 minutes after
experimental application.
In previous studies, antivenom has not been shown to effectively reduce
local tissue damage, even if administered immediately following experimental
envenomation (Russell, 1973; Ownby et al.. 1983; Rucavado and Lomonte,
1996). However, in the present study, antivenom (Lp.) significantly reduced
edema, hemorrhage and myonecrosis induced by CVV venom. Addition of p-
BPB (in saline, i.m.) treatment did not provide any additional reduction in
antivenom treated animals. Thus, it is likely that antivenom is responsible for all
of the in vivo reduction of edema observed with CVV venom. The lack of change
in edema formation seen in those mice treated with DMSO-p-BPB and
antivenom following injection of CVV venom again suggests that DMSO itself
promotes edema by increasing the spread of the venom. Perhaps, the lack of a
significant increase in edema in this case is a result of antivenom negating the
extra edema formation generated by the DMSO, instead of reducing edema as
seen in mice receiving CVV venom followed by only antivenom.
Similar to the edema results, mice treated with antivenom alone and Lm.
saline-p-BPB followed by antivenom after injection of CVV venom showed
significant reductions of hemorrhage. Again, as with edema, antivenom, not p-
BPB alone was probably responsible for the neutralization. Antivenom also
negated the increase in hemorrhage produced by the increased spread of the
venom using the DMSO, resulting in no change of hemorrhagic activity, instead
of reducing the hemorrhage as seen by treating mice only with antivenom
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following injections of CVV venom. Such similar results of edema and
hemorrhage activity following injections of CVV venom followed by antivenom
suggests that the hemorrhagic toxins are responsible for a large portion of the
edema.
Antivenom also reduced myonecrosis induced by CVV venom. All
treatments which included Ax with topical DMSO-p-BPB and i.m. saline-p-BPB
significantly reduced CVV-induced myonecrosis. Neutralization of the
hemorrhagic components, which are abundant in the CVV venom, may be
responsible for the decrease in myonecrosis seen in CVV treated with
antivenom, in vivo. Hemorrhagic toxins produce vascular damage that can
eventually produce ischemia leading to indirect muscle damage (Ownby et al.,
1978; Harris and Cullen, 1990). These toxins require more time to induce this
type of myotoxic damage, as opposed to the direct action of myotoxins
destroying muscle cells, and therefore provides the time necessary for
antivenom to partiaHy inhibit the myonecrosis. Ownby (1990) reported muscle
damage due to ischemia occurring about 4 to 6 hours after injection of some
hemorrhagic toxins.
Similar results were seen with hemorrhage induced by both venoms.
Hemorrhage induced in mice treated with topical DMSO-p-BPB and i.m. saline-p-
BPB and antivenom following injection of ACL venom significantly rose
compared to mice injected only with ACL venom. Just as in the experimental
treatments receiving i.m. saline-p-BPB but not antivenom, the hemorrhage
significantly increased. Typically, neither the topical or i.m. treatments, whether
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followed by antivenom or not, produced any significant changes in myonecrosis
induced by ACL venom.
In comparing the different injection protocols, combining the venom with
the antagonist (in vitro) prior to injection proved to be much more effective than
administerin91 the venom and antagonists separately (in vivo). These results are
consistent with the previous studies by Ownby et al. (1975), Melo et al. (1993)
and Melo et al. (1994) and others working with non-crotalid venom, that also
showed that mixing venom with various antagonists prior to injection provided
greater neutralization of local tissue damage than when antagonist were given
after injection of venom. In both the in vitro and in vivo experiments, antivenom
tended to show an overall greater reduction of local tissue damage than p-BPB.
But in most cases, there were differences in reductions using the antagonists
together that showed more than the additive effects of reduction seen by using
the p-BPB or antivenom separately. Such synergistic effects could be the result
of secondary factors such as a change in pH that enhances the neutralization
capacity of either the p-BPB or the antivenom, or that the pH shift itself is
neutralizing venom components. The next set of experiments should study the
effect of both of these compounds on the individual (purified) hemorrhagic and
myotoxic components, as opposed to the crude venoms, to try to quantify the
amount of local tissue damage produced by each type of toxin. In the present
work, mice which were treated with a topical or i.m. injected antagonist plus
antivenom had no less amount of local tissue damage when compared to mice
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which were treated with only antivenom. In fact, all of the significant changes
were increases in local tissue damage.
n conclusion, antivenom appears to be the best antagonist available for
treating CVV-induced edema, hemorrhage and myonecrosis. However, it is not
very effective for ACL venom. For antagonist such as p-BPB, new methods of
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